Digital Therapeutics Is Moving From Validation to Commercialization — and Hitting Operational Walls
Digital therapeutics — software-based interventions that deliver evidence-based therapeutic functions to treat or manage a disease — have demonstrated clinical validity. The Digital Medicine Society's 2025 landscape report counted more than 160 DTx products with peer-reviewed clinical evidence, up from 74 in 2022. Several have received FDA Breakthrough Device designation or De Novo authorization.
The commercial challenge is a different problem. Payer coverage is expanding but inconsistently. Patient onboarding for software-delivered therapy requires sustained engagement support that many DTx companies are not resourced to deliver at scale. And the FDA Software as a Medical Device (SaMD) regulatory framework continues to evolve, requiring ongoing documentation and compliance management.
Virtual assistants with digital therapeutics and healthcare operations training are helping companies navigate these commercial-scale challenges without the headcount overhead that early-stage companies cannot sustain.
Patient Onboarding and Engagement Support
Digital therapeutics effectiveness depends on patient engagement. Unlike a pill that delivers its intervention passively, a software-based therapy requires the patient to open the application, complete sessions, and maintain consistent use over weeks or months. Research published in the Journal of Medical Internet Research found that DTx completion rates average 42 percent without structured engagement support, compared to 67 percent with proactive patient outreach during the onboarding period.
Virtual assistants provide the engagement support layer: sending onboarding welcome sequences, following up with patients who have not completed initial setup, answering standard technical and usage questions, and escalating clinical questions to licensed staff. This support function is labor-intensive enough that most DTx companies cannot staff it fully in-house during commercial ramp, making VA support a natural fit.
Prescription Digital Therapeutic (PDT) Fulfillment Coordination
For prescription digital therapeutics — software therapies that require a clinician's order — the fulfillment pathway involves prescription verification, patient benefit eligibility confirmation, product access provisioning, and coordinated communication with both the prescribing provider and the patient. Managing this end-to-end workflow across a growing patient volume is operationally demanding.
Virtual assistants handle prescription fulfillment coordination: confirming prescribing provider credentials and NPI validation, communicating coverage determination status to patients, managing access provisioning workflows, and tracking fulfillment timelines. The Association for Behavioral and Cognitive Therapies noted in its 2025 review of digital behavioral health access that prescription fulfillment delays were the most commonly cited patient frustration with prescription DTx products, with a direct correlation to early dropout rates.
FDA SaMD Regulatory Documentation
FDA's evolving SaMD framework — encompassing the Software Precertification Program elements, AI/ML-based SaMD action plans, and updated guidance on predetermined change control plans — requires digital therapeutics companies to maintain active regulatory documentation programs.
Virtual assistants supporting regulatory affairs teams manage documentation for post-market surveillance obligations, track software change documentation against predetermined change control plans, maintain adverse event monitoring files, and coordinate regulatory correspondence. FDA issued updated SaMD guidance in 2025 that expanded documentation requirements for products incorporating adaptive algorithms — creating new compliance workload for companies whose products use machine learning to personalize therapeutic delivery.
Insurance Coverage and Billing Navigation
Payer coverage for digital therapeutics remains fragmented. Some commercial payers have adopted DTx coverage policies; many have not. Medicare coverage for most DTx products remains limited. Navigating this landscape on behalf of patients — verifying coverage before prescriptions are written, managing prior authorization requests for covered products, and appealing denials — requires sustained administrative attention.
Virtual assistants handle payer navigation workflows: running benefit investigations, submitting prior authorization requests, tracking coverage determination timelines, and preparing appeal documentation. For companies working to expand payer coverage through evidence submissions and contract negotiations, VAs also manage the correspondence and documentation logistics of those processes.
The commercial success of DTx companies depends substantially on reducing friction in the payer pathway for patients. VA-supported payer navigation is a material contributor to patient access rates.
For DTx companies looking for virtual assistants who understand the specific operational context of software-delivered therapeutics — including SaMD regulation, PDT fulfillment, and payer navigation — specialist providers like Stealth Agents offer healthcare-trained VAs who can operate effectively in this environment from day one.
The Commercial Window Is Open But Not Indefinitely
Digital therapeutics is moving through a commercialization window where clinical evidence is available but market infrastructure is still maturing. Companies that execute commercial operations efficiently — with well-supported patient onboarding, clean regulatory compliance, and proactive payer navigation — will establish market position and payer relationships that will compound as coverage policies normalize.
Virtual assistants are a practical component of the operational infrastructure that makes that execution possible at early-commercial cost structures.
Sources:
- Digital Medicine Society DTx Landscape Report, 2025
- Journal of Medical Internet Research DTx Engagement Meta-Analysis, 2025
- Association for Behavioral and Cognitive Therapies Digital Health Access Review, 2025
- FDA Software as a Medical Device Guidance Updates, 2025
- Rock Health Digital Therapeutics Market Analysis, 2025